Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Atara Biotherapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 35 | 43 | +8 |
| Shares | 2.41M | 2.37M | −46.2K (−1.9%) |
| Value | $19.6M | $31.5M | +$11.9M (+60.6%) |
New holders (11)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Marshall Wace, LLP | 24,958 | $332.2K | 0.00% |
| Birchview Capital, LP | 22,000 | $292.8K | 0.24% |
| Cubist Systematic Strategies, LLC | 12,682 | $168.8K | 0.00% |
| Northern Trust Corp | 11,170 | $148.7K | 0.00% |
| Point72 Asia (Singapore) Pte. Ltd. | 3,603 | $48.0K | 0.01% |
| SBI Securities Co., Ltd. | 1,416 | $18.8K | 0.00% |
| R Squared Ltd | 240 | $3.19K | 0.00% |
| Jones Financial Companies LLLP | 203 | $2.70K | 0.00% |
| Banque Transatlantique SA | 176 | $2.33K | 0.00% |
| Point72 (DIFC) Ltd | 68 | $905 | 0.00% |
| Alexis Investment Partners, LLC | 28 | $373 | 0.00% |
Sold out (3)
Institutions that held Atara Biotherapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Centiva Capital, LP | 43,403 | $352.9K |
| Global Retirement Partners, LLC | 750 | $6.10K |
| Catalyst Funds Management Pty Ltd | 100 | $813 |